By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Moderna’s personalized mRNA cancer vaccine shows Phase 3 melanoma promise
- Stéphane Bancel describes Moderna and Merck’s positive interim Phase 3 melanoma results combining an individualized mRNA treatment with Keytruda, including meeting recurrence-free survival and distant metastasis-free survival endpoints.
- He explains Keytruda as an immune “checkpoint” therapy that can be highly effective for some patients but leaves a significant fraction without benefit while exposing them to serious immune-related side effects.
- He defines “cancer vaccine” as therapeutic immune education designed to prevent recurrence by teaching the immune system to recognize tumor-specific signals it previously missed.
- He attributes this program’s success to mRNA’s ability (in Moderna’s system) to drive antigen presentation inside immune cells plus deep personalization via tumor/normal DNA sequencing and algorithmic selection of 34 patient-specific targets.
- He outlines the operational and regulatory model for personalized dosing—about 42 days from biopsy to dosing today, manufacturing scaled by compact automated systems, and a process-based regulatory pathway similar to CAR-T.
IDEAS WORTH REMEMBERING
5 ideasModerna’s individualized mRNA therapy showed positive Phase 3 interim results in melanoma beyond Keytruda alone.
He says Moderna and Merck’s melanoma Phase 3 study met its primary endpoint (recurrence-free survival) at an interim analysis, and also met a secondary endpoint (distant metastasis-free survival), which he notes was unexpected at this first interim look.
The combination rationale starts from Keytruda’s limits in both response rates and side effects.
He describes Keytruda as “opening the gates” for the immune system to attack cancer, but says a meaningful portion of patients don’t benefit and can still experience serious immune-related side effects such as autoimmune diseases.
“Vaccine” here means immune education to prevent recurrence, not preventing initial cancer.
He explains that the approach is called a “vaccine” because it teaches the immune system—here, teaching it to recognize cancer signals it previously missed, with the goal of preventing cancer from returning after treatment.
Bancel attributes success to both mRNA-based immune presentation and per-patient personalization.
He argues two things made this work versus prior failed attempts: mRNA delivery/antigen presentation inside antigen-presenting cells, and individualization using tumor-vs-normal DNA comparison plus an algorithmic selection of mutations to encode.
The therapy’s target set is largely unique per patient, making personalization central rather than optional.
He says Moderna selects 34 mutations (“neoantigens”) per patient to stitch into one mRNA, and that Phase 2 analyses suggested about 90% of selected antigens differ from patient to patient—implying personalization is essential.
WORDS WORTH SAVING
5 quotesIt's the first time there is a cancer vaccine working. The field has been doing that for 20-plus years, more than 1,000 clinical trials that have all failed.
— Stéphane Bancel
We're gonna literally compare letter by letter, nucleotide by nucleotide, and then we're gonna use an algorithm to identify of your hundreds of thousands of mutation, which one, based on the current knowledge of the field of immunology and cancer, which one of those mutations are the most relevant.
— Stéphane Bancel
We select the 34 that we believe are the most relevant, and we stitch them together into one big mRNA molecule, which we make in 30-ish days for you, that is injected then in a hospital intramuscularly.
— Stéphane Bancel
The time is around 42 days now, needle to needle, so from taking the biopsy to getting the vaccine in the hospital ready for you.
— Stéphane Bancel
Basically, Jorge, what the FDA wants to know, which is very legitimate, which I would want for my own family's sake, obviously, which is if you give-- If we get the same sample at the beginning, the tumor and the blood, do you get the same product make at the end of a big black box?
— Stéphane Bancel
SPEAKERS
Stéphane Bancel
guestCEO of Moderna, leading development and commercialization of mRNA-based medicines and vaccines.
Jorge Conde
hostGeneral Partner on the a16z biohealth team and host of the a16z podcast.
High quality AI-generated summary created from speaker-labeled transcript.
